Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares Bought by GSA Capital Partners LLP

Key Points

• GSA Capital Partners LLP significantly increased its stake in Amphastar Pharmaceuticals, owning 45,297 shares after a 159.8% increase during Q1, valued at approximately $1.31 million.
• Other institutional investors also raised their positions in Amphastar, with TD Asset Management Inc increasing holdings by 20.2% and Boston Trust Walden Corp by 24.2% during the same quarter.
• An analyst downgrade has affected the stock’s outlook, with JPMorgan reducing its price target from $45.00 to $30.00, while the average rating has been set at "Hold" with a consensus target price of $32.33.

GSA Capital Partners LLP raised its position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 159.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 45,297 shares of the company's stock after buying an additional 27,863 shares during the quarter. GSA Capital Partners LLP owned about 0.10% of Amphastar Pharmaceuticals worth $1,313,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. TD Asset Management Inc boosted its holdings in Amphastar Pharmaceuticals by 20.2% during the 1st quarter. TD Asset Management Inc now owns 2,212,142 shares of the company's stock valued at $64,130,000 after acquiring an additional 371,856 shares during the period. Systematic Financial Management LP bought a new position in Amphastar Pharmaceuticals during the 4th quarter valued at approximately $9,147,000. Royce & Associates LP increased its position in Amphastar Pharmaceuticals by 2,684.3% during the 1st quarter. Royce & Associates LP now owns 247,858 shares of the company's stock valued at $7,185,000 after buying an additional 238,956 shares in the last quarter. Boston Trust Walden Corp raised its stake in shares of Amphastar Pharmaceuticals by 24.2% in the first quarter. Boston Trust Walden Corp now owns 1,215,624 shares of the company's stock worth $35,241,000 after purchasing an additional 236,704 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in shares of Amphastar Pharmaceuticals by 9.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,198,590 shares of the company's stock worth $44,503,000 after purchasing an additional 105,288 shares during the last quarter. 65.09% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms have issued reports on AMPH. Needham & Company LLC reissued a "hold" rating on shares of Amphastar Pharmaceuticals in a report on Thursday, April 10th. Wells Fargo & Company decreased their target price on Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating on the stock in a research report on Thursday, May 8th. Finally, JPMorgan Chase & Co. reiterated a "neutral" rating and issued a $30.00 target price (down from $45.00) on shares of Amphastar Pharmaceuticals in a research report on Monday, May 12th. Four research analysts have rated the stock with a hold rating and one has given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $32.33.

Amphastar Pharmaceuticals Trading Up 1.2%

NASDAQ:AMPH traded up $0.26 during midday trading on Friday, hitting $21.21. The stock had a trading volume of 440,154 shares, compared to its average volume of 454,819. Amphastar Pharmaceuticals, Inc. has a one year low of $20.39 and a one year high of $53.96. The company has a market capitalization of $999.84 million, a price-to-earnings ratio of 7.68 and a beta of 0.76. The stock has a 50-day moving average of $23.71 and a 200 day moving average of $26.69. The company has a quick ratio of 2.02, a current ratio of 2.95 and a debt-to-equity ratio of 0.80.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.